Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Simple exercises may boost nerve repair in diabetic neuropathy

NCT ID NCT07675720

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study compares two exercise programs—combined aerobic and resistance training versus seated soleus push-ups—against standard care in people with type 2 diabetes and diabetic peripheral neuropathy. Researchers will measure blood markers of nerve repair (BDNF, NGF, S100B) and assess changes in symptoms, balance, and quality of life over 8 weeks. The goal is to identify which exercise approach best supports nerve health and function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
exercise (concurrent training or soleus push-ups)
What this could lead to
If effective, these exercises could offer a simple, drug-free way to support nerve repair and reduce symptoms of diabetic neuropathy.
What could go wrong
This is a small, early-stage trial measuring biological markers, not clinical outcomes. Results may not translate to meaningful symptom improvement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 99 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 40-65 years * Diagnosed Type 2 Diabetes Mellitus (T2DM) Confirmed diagnosis of T2DM for at least 5 years. * Confirmed Diabetic Peripheral Neuropathy (DPN) Diagnosis is based on clinical evaluation and scoring tools such as: * Michigan Neuropathy Screening Instrument (MNSI) Cut-off value of ≥4 for Part A (History)(104) Cut-off value of ≥2 from Part B (Examination)(105) * Vibration Pressure Threshold (≥25 Volts)(106) * HbA1c between 6.5% and 9.0% Reflecting moderate glycemic control, patients with extremely poor control were excluded for safety. * Stable medication regimen No changes in antidiabetic, antihypertensive, or neuropathy medications in the past 3 months. * Sedentary or low physical activity level Based on standard questionnaires (International Physical Activity Questionnaire - IPAQ), not currently engaged in structured exercise programs. * Ability to walk independently To ensure safety during aerobic or resistance exercise (for Group A). * Able to understand and follow instructions * Consent to participate and comply with study protocol * Written informed consent, obtained before randomization Exclusion Criteria: * History of recent cardiovascular events Includes myocardial infarction, stroke, or any cardiac intervention within the past 6 months. * Uncontrolled hypertension Blood pressure ≥160/100 mmHg at rest. * Severe musculoskeletal disorders or physical disability Including joint deformities, fractures, or amputation that limit the ability to perform exercise. * Severe diabetic foot ulcers or active lower limb infection Increases risk during lower limb activity or exercise. * End-stage renal disease (CKD stage 4 or higher) Associated systemic complications may confound study outcomes or affect safety. * Severe retinopathy or proliferative diabetic eye disease Exercise may pose risks such as retinal hemorrhage. * Current Smoker, tobacco or alcohol consumer. That may affect the blood biomarkers. * Cognitive impairment or psychiatric disorders That may affect understanding, compliance, or safety during exercise. * Participation in a structured exercise program within the last 3 months To avoid training-induced bias and ensure a sedentary baseline. * Chronic inflammatory or autoimmune conditions Conditions like rheumatoid arthritis or lupus may alter neurotrophic biomarkers. * Use of medications affecting neurogenesis or metabolism Such as corticosteroids, antipsychotics, or immunosuppressants. * Diagnosed sleep disorder * That may affect the outcomes of the intervention. * Pregnancy or lactation Due to altered physiology and ethical concerns.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic peripheral neuropathy type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Pakistan Railways General Hospital and Mediplex Healthcare Center

    Rawalpindi, 46210, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.